ストックスクリーナーアプリを入手
1.73
2.37%
0.04
前日終値:
$1.69
開ける：
$1.69
24時間の取引高:
1.69M
Relative Volume:
1.35
時価総額：
$118.88M
収益：
-
当期純損益:
$-89.66M
株価収益率:
-0.7147
EPS:
-2.4205
ネットキャッシュフロー:
$-81.90M
1週間 パフォーマンス:
+4.22%
1か月 パフォーマンス:
-67.51%
6か月 パフォーマンス:
-64.62%
1年 パフォーマンス:
+32.06%
1日の値動き範囲:
$1.65
$1.765
1週間の範囲:
$1.57
$1.80
52週間の値動き範囲:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Compare PEPG vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.72 | 116.80M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
442.53 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.55 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
841.84 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.44 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.29 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-09 | 開始されました | Guggenheim | Buy |
| 2024-12-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-07-31 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-21 | 開始されました | H.C. Wainwright | Buy |
Pepgen Inc (PEPG) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts - National Today
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks
Signal Recap: Should I set a stop loss on PepGen Inc2026 Pullback Review & Technical Confirmation Alerts - baoquankhu1.vn
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
PepGen team joins Kansas City event to drive myotonic dystrophy research discussions - Traders Union
Rate Cut: Does PepGen Inc have declining or rising EPSAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
PepGen joins MyotonicStrong conference to present clinical progress - Traders Union
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
Retail Trends: Is PepGen Inc forming a breakout pattern2026 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-04-07 21:04:49 - baoquankhu1.vn
PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PEPG Technical Analysis & Stock Price Forecast - Intellectia AI
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView — Track All Markets
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients - MarketScreener
PepGen's 5 mg/kg Data Outlier: Is This a Prelude to a 10 mg/kg Comeback or Evidence of a Failed Strategy? - Bitget
PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief - Seeking Alpha
PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade
PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease - BioSpace
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
A Quick Look at Today's Ratings for PepGen(PEPG.US), With a Forecast Between $3 to $20 - news.futunn.com
Why PEPG, SGMO, PHR are among top premarket losers today - MSN
Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating - marketscreener.com
Why Is PepGen Stock Sinking Tuesday? - Benzinga
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT DataSlideshow (NASDAQ:PEPG) 2026-03-31 - Seeking Alpha
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - BioSpace
PepGen reports ‘promising’ topline results from MAD cohort - TipRanks
PepGen stock tumbles 44% on disappointing trial results By Investing.com - Investing.com Canada
Movement Recap: Should I set a stop loss on PepGen Inc2026 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data - TipRanks
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing By Investing.com - Investing.com Australia
PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView — Track All Markets
[8-K] PepGen Inc. Reports Material Event - Stock Titan
Pepgen Inc (PEPG) 財務データ
収益
当期純利益
現金流量
EPS
Pepgen Inc (PEPG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Donnelly Noel | Chief Financial Officer |
Mar 04 '26 |
Sale |
6.23 |
2,084 |
12,988 |
111,603 |
| McArthur James G | President and CEO |
Mar 04 '26 |
Sale |
6.23 |
5,275 |
32,876 |
296,326 |
| Oxford Science Enterprises plc | Former 10% Owner |
Sep 30 '25 |
Buy |
3.20 |
200,000 |
640,000 |
4,955,388 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Sep 26 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
18,554,273 |
| STRECK PAUL | EVP, Head of R&D |
May 30 '25 |
Buy |
1.24 |
8,375 |
10,393 |
27,805 |
| McArthur James G | President and CEO |
Apr 17 '25 |
Buy |
1.35 |
10,000 |
13,550 |
113,913 |
2.68%
0.34%
大文字化:
|
ボリューム (24 時間):